Results 21 to 30 of about 414,323 (331)

Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins

Cell Death and Disease, 2023
Bruton’s tyrosine kinase inhibitors (BTKi) and CAR T-cell therapy have demonstrated tremendous clinical benefits in mantle cell lymphoma (MCL) patients, but intrinsic or acquired resistance inevitably develops.
Yijing Li, Heng-Huan Lee, Vivian Changying Jiang, Yuxuan Che, Joseph McIntosh, Alexa Jordan, Jovanny Vargas, Tianci Zhang, Fangfang Yan, Margaret Elizabeth Simmons, Wei Wang, Lei Nie, Yixin Yao, Preetesh Jain, Michael Wang, Yang Liu   +15 more
doaj   +1 more source

Multiple Myeloma

Nature Reviews Disease Primers
Multiple myeloma (MM) is a haematological lymphoid malignancy involving tumoural plasma cells and is usually characterized by the presence of a monoclonal immunoglobulin protein. MM is the second most common haematological malignancy, with an increasing global incidence.
Keivan Daneshvar, Wolfram A. Bosbach, Nando Mertineit, G Nöldge, Frank Mosler   +4 more
openalex   +5 more sources

Serum Free Light Chains Removal by HFR Hemodiafiltration in Patients with Multiple Myeloma and Acute Kidney Injury. a Case Series [PDF]

, 2018
Background/Aims: Multiple myeloma (MM) represents 10% of all haematologic malignancies. Renal involvement occurs in 50% of MM patients; of them, 12-20% have acute kidney injury (AKI), with 10% needing dialysis at presentation. While hemodialysis (HD) has
Antolino, Giusy, Festuccia, Francescaromana, Fofi, Claudia, Giammarioli, Elisa, La Verde, Giacinto, Mene, Paolo, Punzo, Giorgio, Tafuri, Agostino   +7 more
core   +2 more sources

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

Nature Communications, 2017
In multiple myeloma, malignant cells expand within bone marrow. Here, the authors use multi-region sequencing in patient samples to analyse spatial clonal architecture and heterogeneity, providing novel insight into multiple myeloma progression and ...
L. Rasche, S. S. Chavan, O. W. Stephens, P. H. Patel, R. Tytarenko, C. Ashby, M. Bauer, C. Stein, S. Deshpande, C. Wardell, T. Buzder, G. Molnar, M. Zangari, F. van Rhee, S. Thanendrarajan, C. Schinke, J. Epstein, F. E. Davies, B. A. Walker, T. Meissner, B. Barlogie, G. J. Morgan, N. Weinhold   +22 more
doaj   +1 more source

Advances in the design and development of oncolytic measles viruses. [PDF]

, 2015
A successful oncolytic virus is one that selectively propagates and destroys cancerous tissue without causing excessive damage to the normal surrounding tissue. Oncolytic measles virus (MV) is one such virus that exhibits this characteristic and thus has
Hutzen, Brian, Raffel, Corey, Studebaker, Adam W   +2 more
core   +1 more source

Mathematical modelling of the pathogenesis of multiple myeloma-induced bone disease [PDF]

, 2014
Multiple myeloma (MM) is the second most common haematological malignancy and results in destructive bone lesions. The interaction between MM cells and the bone microenvironment plays an important role in the development of the tumour cells and MM ...
Blum B, Eriksen EF, Klein B, Lipton A, Mundy GR, Schmitt CP, Shay G   +6 more
core   +1 more source

γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation

Blood Cancer Journal, 2022
We here defined the impacts of γ-secretase inhibitors (GSIs) on T-cell-dependent BCMA-specific multiple myeloma (MM) cell lysis and immunomodulatory effects induced by bispecific antibodies (BisAbs).
Hailin Chen, Tengteng Yu, Liang Lin, Lijie Xing, Shih-Feng Cho, Kenneth Wen, Kimberly Aardalen, Adwait Oka, Joni Lam, Mike Daley, Haihui Lu, Nikhil Munshi, Kenneth C. Anderson, Yu-Tzu Tai   +13 more
doaj   +1 more source

Gene Co-expression Network and Copy Number Variation Analyses Identify Transcription Factors Associated With Multiple Myeloma Progression [PDF]

, 2019
Multiple myeloma (MM) has two clinical precursor stages of disease: monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). However, the mechanism of progression is not well understood.
Abu Zaid, Mohammad, Han, Zhi, Huang, Kun, Huang, Zhi, Johnson, Travis S., Xiang, Shunian, Yu, Christina Y., Zhan, Xiaohui   +7 more
core   +5 more sources

JNK signalling in cancer: In need of new, smarter therapeutic targets [PDF]

, 2013
Copyright © 2013 The British Pharmacological Society. This is the accepted version of the following article: Bubici, C. and Papa, S. (2014), JNK signalling in cancer: in need of new, smarter therapeutic targets.
Adams, Ahmed, Anbalagan, Annunziata, Antonyak, Bain, Barbarulo, Barr, Behrens, Bennett, Bharti, Bogoyevitch, Bogoyevitch, Borsello, Bost, Carboni, Cazanave, Cellurale, Cellurale, Cellurale, Chang, Chang, Chauhan, Chen, Chen, Chen, Chen-Deutsch, Cho, Choi, Chromik, Cilloni, Cripe, Cui, Cui, Das, Davis, Deininger, Dérijard, Eferl, Estey, Farazi, Ferrandi, Finegan, Fuchs, Gaillard, Gao, Gao, Gilmore, Goenka, Graff, Gururajan, Hagiwara, He, Heo, Hess, Hideshima, Hideshima, Hideshima, Hirosumi, Ho, Huang, Hui, Hunot, Jaeschke, Jagtap, Jemal, Johnson, Kamenecka, Kaneto, Kaoud, Ke, Keats, Kersting, Kuan, Kuperwasser, Li, Llovet, Lloyd, LoGrasso, Luedde, Maclean, Maeda, Mamay, Manning, Manning, Min, Mucha, Murati, Nagata, Nateri, Ngoei, Ngoei, Nitta, Oleinik, Owens, Papa, Papa, Plantevin Krenitsky, Qiu, Raitano, Reinecke, Ricard, Rodrigues, Ronaldson, Roy, Sabapathy, Sakurai, Schramek, Seki, She, Siddiqui, Smeal, Srivastava, Stebbins, Su, Su, Szczepankiewicz, Takahashi, Tong, Tournier, Tsuiki, Waetzig, Wagner, Wang, Wang, Webster, Whitmarsh, Whitmarsh, Yamamoto, Yan, Yang, Yao, Yoon, Yoshida, Zhang, Zhang, Zhang, Zhang   +137 more
core   +2 more sources

Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum

Leukemia Research Reports, 2023
To evaluate the specific prognostic value of CAs, we conducted an analysis of 923 symptomatic multiple myeloma patients. Among this cohort, 480 patients had complete data set of high-risk CAs by interphase fluorescent in situ hybridization at diagnosis ...
Aya Nakaya, Hirohiko Shibayama, Nobuhiko Uoshima, Ryosuke Yamamura, Satoshi Yoshioka, Kazunori Imada, Yuji Shimura, Masaaki Hotta, Toshimitsu Matsui, Satoru Kosugi, Hitoshi Hanamoto, Hitoji Uchiyama, Satoshi Yoshihara, Shin-ichi Fuchida, Yoshiyuki Onda, Yasuhiro Tanaka, Kensuke Ohta, Mitsuhiro Matsuda, Junya Kanda, Adachi Yoko, Miki Kiyota, Eri Kawata, Ryoichi Takahashi, Kentaro Fukushima, Hirokazu Tanaka, Hideo Yagi, Teruhito Takakuwa, Naoki Hosen, Tomoki Ito, Chihiro Shimazaki, Akifumi Takaori-Kondo, Junya Kuroda, Itaru Matsumura, Masayuki Hino   +33 more
doaj   +1 more source